Teenagers turn to cancer drug in online quest to grow taller, risking serious health complications

Relevant News

Teenagers are putting their health at risk by following a new online trend that promises extra centimetres in height through the use of powerful medication.

On social media, where discussions about so-called heightmaxxing have gained traction in Europe and the United States, an anti-cancer drug has attracted particular attention after being linked to unusually rapid growth in children treated for brain tumours.

Behind the extra centimetres, however, lies a very different reality. One child who grew 14.3 centimetres in just nine months eventually needed surgery after developing a serious complication, prompting intervention by the European Medicines Agency (EMA).

Two Cypriot experts, pharmacy professor Christos Petrou and paediatric endocrinologist Nikos Skordis, have warned Phileleftheros that using powerful medication for the sole purpose of increasing height in otherwise healthy teenagers can have serious consequences.

The drug at the centre of the controversy is erdafitinib, a powerful targeted cancer treatment approved for certain adults with advanced urothelial cancer. It has also been used in research settings or off-label to treat specific brain tumours in children.

Reports of unusually rapid height increases emerged from its use in children, fuelling online discussions. But this growth is not a therapeutic benefit for healthy teenagers. It is associated with disruptions to normal bone development.

The reports reached the European Medicines Agency, which, following an assessment, established a causal relationship between erdafitinib use in children and certain disorders affecting skeletal development.

The concern is that a drug used to treat serious forms of cancer has now become part of discussions surrounding heightmaxxing – an online trend encouraging social media users to seek ways of increasing their height, including through unapproved medical interventions.

Despite the growing attention surrounding the trend, there is no reliable evidence showing how many teenagers have actually used erdafitinib in an attempt to grow taller.

Teenagers experiment as children end up needing surgery

While scientists warn about the risks, teenagers on social media are reportedly experimenting with erdafitinib, documenting their height increases and exchanging information about the side effects they experience.

The US magazine Rolling Stone has published accounts from teenagers who said they were taking the anti-cancer drug to grow taller, despite the potentially serious effects on their health.

A 17-year-old from New York said he had started taking the medication at the age of 15. He described severe joint pain, dry skin and nosebleeds, while another teenager of the same age reported serious problems with his nails.

At the same time, TikTok posts are attracting the interest of other teenagers, some of whom are seeking information on how to obtain the drug. According to international media reports, the platform has blocked some accounts promoting the practice.

These personal accounts have not been independently verified through medical records. However, serious complications have been documented in children who received erdafitinib as cancer treatment.

One notable case involved a 15-year-old boy who was taking the drug for a brain tumour. His height increased by 14.3 centimetres in approximately nine months. However, the dramatic growth was accompanied by severe spinal deformities that required surgery. He was not the only child affected.

A scientific paper by researchers at the US Food and Drug Administration (FDA) documents five cases involving children aged between 10 and 15 who developed serious adverse effects affecting skeletal development while taking erdafitinib.

Three of the five children required surgery, while treatment with the drug was permanently discontinued in all five cases.

These cases involved children receiving cancer treatment, not healthy teenagers taking the medication to increase their height.

Christos Petrou: Growing taller does not mean developing healthily

Explaining how the drug works to Phileleftheros, pharmacy professor Christos Petrou said erdafitinib inhibits receptors involved in the development of certain tumours.

One of these, FGFR3, normally plays a role in regulating bone elongation by acting as a mechanism that limits bone growth.

Inhibiting its activity can affect the rate at which a child’s bones develop.

However, Professor Petrou stressed that faster growth over a few months does not necessarily mean a child will be taller as an adult.

“The fact that a child grows faster for a few months does not mean they will be taller as an adult,” he said.

Petrou said there was no clinical evidence demonstrating that erdafitinib could safely increase the final adult height of healthy teenagers.

Accelerated growth is an adverse effect of the medication, not an approved therapeutic use.

Nikos Skordis: Serious risks for teenagers

Paediatric endocrinologist Nikos Skordis also warned Phileleftheros about the risks associated with taking the drug.

He explained that although erdafitinib may be associated with increased height, this does not mean the resulting growth is beneficial for a child’s development.

He warned of the serious side effects the medication can cause, stressing that skeletal development should not be viewed simply in terms of gaining extra centimetres.

Skordis made clear that the anti-cancer drug should not be taken by healthy teenagers to make themselves taller and highlighted the dangers of such a practice.

What the European Medicines Agency found

The seriousness of the issue is also reflected in the official assessment by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC).

The committee examined information from the European adverse drug reaction database, EudraVigilance, scientific literature and a cumulative review submitted by the marketing authorisation holder.

It concluded that there was sufficient evidence to establish a causal relationship between erdafitinib and accelerated growth or slipped capital femoral epiphysis in children who had received the drug off-label.

Slipped capital femoral epiphysis is a serious condition in which the head of the thigh bone shifts in relation to its neck at the growth plate. It can cause pain, limping and problems with hip function.

The PRAC requested an update to the drug’s European product information to include these specific adverse effects.

Meanwhile, US safety information for the drug also lists risks affecting children’s skeletal development. Other known serious adverse effects of erdafitinib include vision problems and disturbances in phosphate levels in the blood.

Follow en.philenews on Google News and be the first to know all the news about Cyprus and the world.